Filing Flows

Filing Flows › Companies › 60 Degrees Pharmaceuticals › Cash flow

60 Degrees Pharmaceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.2M in Q2 2026 · −$8.9M over twelve months

Operating cash flow−$2.2M
Free cash flow−$2.2M
Cash conversion cycle-79 days

Analysis

In Q2 2026, 60 Degrees Pharmaceuticals generated −$2.2M of operating cash flow. That is $734K less than in Q2 2025 (−$1.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$8.8M; the largest uses were operating cash flow ($8.8M), other investing ($168K), capital spending ($120K); besides operations, cash came from other financing ($8.1M); the cash balance fell by $944K.

Operating cash flow was −$2.2M against net income of −$2.3M. The largest differences: prepaid and other assets +$361K, payables −$263K, receivables −$231K.

Its cash conversion cycle was -79 days (receivables 198 + inventory 539 − payables 815): suppliers fund its working capital.

Free cash flow

60 Degrees Pharmaceuticals: free cash flow by quarter60 Degrees Pharmaceuticals: free cash flow by quarter−$1.7MQ3 2024−$1.6MQ4 2024−$1.6MQ1 2025−$1.5MQ2 2025−$2.1MQ3 2025−$1.8MQ4 2025−$2.8MQ1 2026−$2.2MQ2 2026
Operating cash flow less capital spending.
60 Degrees Pharmaceuticals: operating cash flow against capital spending60 Degrees Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$1.7M$14KQ3 2024−$1.6M$0Q4 2024−$1.6M$3KQ1 2025−$1.5M$47KQ2 2025−$2.1M$10KQ3 2025−$1.7M$80KQ4 2025−$2.7M$30KQ1 2026−$2.2M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.2M, Capital spending $0.

Capital allocation, year by year

60 Degrees Pharmaceuticals: where the cash came from (up) and went (down), by fiscal year60 Degrees Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2022: Operating cash flow −$1.0MFY2022: Net borrowing $985KFY2022: Shares issued $1.0M$2.0MFY2022FY2023: Operating cash flow −$4.5MFY2023: Net borrowing −$711KFY2023: Shares issued $1.0MFY2023: Capital spending −$58K$1.0MFY2023FY2024: Operating cash flow −$5.6MFY2024: Asset sales $11KFY2024: Capital spending −$104K$11KFY2024FY2025: Operating cash flow −$6.8MFY2025: Capital spending −$140KFY2025
Over these 4 years operating cash flow totalled −$18.1M; the largest uses were operating cash flow ($18.1M) and net borrowing ($711K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.3M
Debt$150K
Net cash$2.1M
Due within a year$1K
Cash runway3 months

60 Degrees Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$8.9M a year at the current rate against $2.3M of cash and investments: a runway of about 3 months; $1K of debt also comes due within a year, which would need refinancing or new money before any new financing.

60 Degrees Pharmaceuticals: debt maturities by year (FY2025)60 Degrees Pharmaceuticals: debt maturities by year (FY2025)$1KYear 1$3KYear 2$3KYear 3$3KYear 4$4KYear 5$136KAfter year 5
Principal due in each year as disclosed in the annual report, against $2.3M of cash and investments now.

Where the cash came from and went

60 Degrees Pharmaceuticals: sources (+) and uses (−) of cash, Q2 202660 Degrees Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$2.3MOperating cash flow−$2.2MOther investing−$86KExchange rates$3K
60 Degrees Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 202660 Degrees Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$8.8MOther financing$8.1MCash drawn (+) / kept (−)$944KOther investing−$168KCapital spending−$120KExchange rates$8K

From profit to cash

60 Degrees Pharmaceuticals: net income to operating cash flow, Q2 202660 Degrees Pharmaceuticals: net income to operating cash flow, Q2 2026Net income−$2.3MDepreciation & amortization$31KStock-based pay$98KReceivables−$231KInventory$33KPayables−$263KPrepaid and other assets$361KOperating cash flow−$2.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026198539815-79
Q1 20262358231547-489
Q4 20251794511087-456
Q3 202510211319719
Q2 202535314301876-93
Q1 20252687471330-315
Q4 2024154349657-154
Q3 202421136254428

Every quarter

QuarterOperating cash flowCapital spendingCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.2M—$2.3M−$2.2M
Q1 2026−$2.7M−$30K−$1.8M−$2.8M
Q4 2025−$1.7M−$80K$2.6M−$1.8M
Q3 2025−$2.1M−$10K−$2.1M−$2.1M
Q2 2025−$1.5M−$47K$1.5M−$1.5M
Q1 2025−$1.6M−$3K−$1.8M−$1.6M
Q4 2024−$1.6M—$1.6M−$1.6M
Q3 2024−$1.7M−$14K−$1.7M−$1.7M

60 Degrees Pharmaceuticals: income statement and cash flow

60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year). The chart follows the revenue to costs, profit and cash.

60 Degrees Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.